SCHEMBL3311518

SCHEMBL3311518

CC(=CC(C)OS(=O)(=O)O)C(=O)O

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL8444187 0.98 APEX1 (0.31) APEX1
SCHEMBL8441447 0.74
SCHEMBL13685332 0.74 APEX1 (0.35) APEX1
SCHEMBL536916 0.74 APEX1 (0.35) APEX1
SCHEMBL3311523 0.72 APEX1 (0.31) APEX1
SCHEMBL8150337 0.72 TSHR (0.44) APEX1
SCHEMBL13685385 0.72 TSHR (0.33) APEX1
SCHEMBL151234 0.72 APEX1 (0.36) APEX1
SCHEMBL642406 0.72 TSHR (0.33) APEX1
SCHEMBL7639061 0.72 APEX1 (0.36) APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2544812-B1 IMPROVED MICROCAPSULES AND PRODUCTION THEREOF FOLLMANN GMBH & CO KG (DE) 2018-10-24 EP claimed
EP-0831932-A4 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP (US) 2000-01-12 EP claimed
EP-0831932-A1 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1998-04-01 EP claimed
WO-1996040285-A1 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1996-12-19 WO claimed
US-8591949-B2 Aqueous compositions comprising a chemical microgel associated with an aqueous polymer RHODIA CHIMIE (FR) 2013-11-26 US disclosed
US-8497062-B2 Resin for formation of upper antireflective film, composition for formation of upper antireflective film, and resist pattern formation method JSR CORPORATION (JP) 2013-07-30 US disclosed
US-7820752-B2 Use of charged amphiphilic statistic polymers for thickening phase comprising giant micelles of surfactants and aqueous composition comprising same RHODIA CHIMIE (FR) 2010-10-26 US disclosed
US-20100112475-A1 RESIN FOR FORMATION OF UPPER ANTIREFLECTIVE FILM, COMPOSITION FOR FORMATION OF UPPER ANTIREFLECTIVE FILM, AND RESIST PATTERN FORMATION METHOD JSR CORPORATION (JP) 2010-05-06 US disclosed
US-7589144-B2 The inverse emulsion comprising an internal aqueous phase that has hydrophilic active substance dispersed in an organic phase and an external aqueous phase comprising polyalkoxylated amphiphilic nonionic polymer (or surfactant), and a water-soluble or water-dispersible polymer; easy storage, transporting RHODIA CHIMIE (FR) 2009-09-15 US disclosed
US-7579400-B2 Particles having an organized internal structure which are dispersed in an aqueous phase, the preparation thereof and use of same RHODIA CHIMIE (FR) 2009-08-25 US disclosed
US-20090131578-A1 Aqueous Compositions Comprising A Chemical Microgel Associated With An Aqueous Polymer RHODIA CHIMIE (FR) 2009-05-21 US disclosed
US-7319117-B2 Method for preparing a water/oil/water multiple emulsion RHODIA CHIMIE (FR) 2008-01-15 US disclosed
US-20050169946-A1 Cosmetic formulation comprising at least two active substances in a multiple emulsion optionally mixed with a single emulsion CHIMIE, RHODIA (FR) 2005-08-04 US disclosed
US-20050119401-A1 Use of charged amphiphilic statistic polymers for thickening phase comprising giant micelles of surfactants and aqueous composition comprising same RHODIA CHIMIE (FR) 2005-06-02 US disclosed
US-20050053569-A1 Use of cationic block copolymers to assist the deposition of simple or multiple emulsions RHODIA CHIMIE (FR) 2005-03-10 US disclosed
US-20050019352-A1 Method for preparing a water/oil/water multiple emulsion RHODIA CHIMIE (FR) 2005-01-27 US disclosed
US-20040219215-A1 Aqueous compositions comprising a chemical microgel associated with an aqueous polymer RHODIA CHIMIE (FR) 2004-11-04 US disclosed
US-20040213854-A1 can make available high concentrations of active material(s) in solid formulations, and also make possible a release that is spread over time and/or triggered from said active ingredient, once the formulation has been applied CHIMIE, RHODIA (FR) 2004-10-28 US disclosed
US-20040170657-A1 Dispersion comprising an emulsion having an aqueous phase with high ionic strength RHODIA CHIMIE (FR) 2004-09-02 US disclosed
US-20040054076-A1 Method for preparing an emulsion with high-viscosity organic phase RHODIA CHIMIE (FR) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050053569-A1 Use of cationic block copolymers to assist the deposition of simple or multiple emulsions ABCB4, APOB, CHMP4B APEX1 1595/4885
US-20040170657-A1 Dispersion comprising an emulsion having an aqueous phase with high ionic strength SAMM50, IPO5, IPO7 APEX1 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.